SCHEMBL16201385

SCHEMBL16201385

CCCN(C)Cc1c[nH]nc1-c1cccc(F)c1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.38
KDM4E B2RXH2 2/20 0.38
TDP1 Q9NUW8 2/20 0.35
RECQL P46063 1/20 0.35
ACHE P22303 4/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
HDAC1 Q13547 2/20 0.34
HDAC6 Q9UBN7 2/20 0.34
ALDH1A1 P00352 3/20 0.33
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
HTT P42858 1/20 0.33
POLB P06746 1/20 0.32
PDCD1 Q15116 1/20 0.32
CD274 Q9NZQ7 1/20 0.32
PRMT3 O60678 1/20 0.32
CARM1 Q86X55 1/20 0.32
PRMT6 Q96LA8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16201222 0.90 CARM1 (0.41) LMNAKDM4ETDP1RECQLACHE
SCHEMBL16201351 0.89 LMNA (0.44) LMNAKDM4ETDP1RECQLACHE
SCHEMBL16201417 0.82 MEN1 (0.39) LMNAKDM4ETDP1ACHEALDH1A1
SCHEMBL16201388 0.82 CFD (0.34) LMNAKDM4ETDP1RECQLPRMT3
SCHEMBL16201360 0.81 ALDH1A1 (0.36) LMNAKDM4ETDP1RECQLSMN1; SMN2
SCHEMBL16201356 0.79 ALDH1A1 (0.41) LMNAKDM4ETDP1RECQLSMN1; SMN2
SCHEMBL16201165 0.79 LMNA (0.44) LMNAKDM4ETDP1RECQLACHE
SCHEMBL16201381 0.79 CRHR1 (0.41) LMNAKDM4ETDP1KMT2AMEN1
SCHEMBL16201406 0.78 TDP1 (0.34) LMNAKDM4ETDP1RECQLALDH1A1
SCHEMBL16201411 0.78 ALDH1A1 (0.39) LMNAKDM4ETDP1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9776972-B2 Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof EPIZYME INC. (US) 2017-10-03 US disclosed
US-9346761-B2 Arginine methyltransferase inhibitors and uses thereof Epizyme, Inc. (US) 2016-05-24 US disclosed
US-20160137609-A1 PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-05-19 US disclosed
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 LMNA 3763/4885KDM4E 157/4885TDP1 317/4885
US-20160137609-A1 PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 LMNA 4321/4885KDM4E 288/4885TDP1 375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.